PSNL earnings call summary

Prepared Highlights

• Q2 2025 total revenue $17.2M, down 24% YoY from $22.6M (prepared); decline driven by $5.6M expected volume decline from Natera and $1.3M from Moderna (CFO).
• Biopharma revenue $11.1M, down 16% YoY from $13.2M (CFO); would have increased YoY without customer project delays (CEO, CFO). NeXT Personal biopharma revenue on track for 300–400% YoY growth (CEO).
• Clinical test volume: 3,478 tests delivered in Q2, up 59% sequentially and 575% YoY (CEO). Base of ordering physicians expanded to over 600 (CEO).
• Clinical revenue from NeXT Dx and NeXT Personal tests $0.5M vs. $0.1M in prior year (CFO).
• Gross margin 27.6% (Q2) vs. 35.6% prior year; unreimbursed clinical test costs impacted margin by ~12%; ex those costs, gross margin ~40% (CFO).
• Operating expenses $26.6M vs. $24.9M prior year; increase tied to selling expenses for clinical volume growth (CFO).
• Net loss $20.1M vs. $12.8M prior year (prior year included $3M noncash gain from Tempus warrants) (CFO).
• Cash & short-term investments $173.2M at quarter end; cash usage from ops & capex $13.2M in Q2 (CFO). Full-year cash usage expected ~$75M (CFO).
• Official guidance (Q3 2025) : total revenue $12M–$14M; pharma test services & other $11M–$13M; population sequencing & enterprise ~$1M (CFO).
• Official guidance (FY 2025, revised) : total revenue $70M–$80M (from $80M–$90M); pharma test services & other $52M–$58M; population sequencing & enterprise $15M–$16M; clinical tests reimbursed $3M–$6M; gross margin 22–24% ; net loss ~$85M (including ~$20M unreimbursed test costs); cash usage ~$75M (CFO).
• NeXT Personal commercial partnership with Tempus expanded to breast, lung, colorectal cancer and immunotherapy monitoring (CEO).
• Targeting Medicare coverage for at least 2 indications by end of 2025 ; IO monitoring dossier submitted; lung cancer dossier on track (CEO).
• Adding to own sales force; expect to exit 2025 with 12–15 field professionals (CEO).
• New customers from prior call on track to generate over $5M each in revenue this year (CEO).
• Natera business expected to conclude by end of Q3 2025 (CFO).

Mgmt Quotes

• “The clinical adoption of NeXT Personal is accelerating dramatically with test volume growing 59% sequentially.” (CEO)
• “We believe we're on a path towards securing Medicare coverage for 2 indications by the end of this year.” (CEO)
• “We own the Q2 revenue shortfall. Moving forward, we're pushing hard on the levers we can control to finish the year strong instead of passively waiting for market conditions to change.” (CEO)
• “An important study from AstraZeneca showed our test detecting cervical cancer progression up to 16 months ahead of imaging.” (CEO)
• “We continue to expect total company margins to expand beyond 50% once we have obtained reimbursement coverage for more than a few indications and we achieve scale.” (CFO)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Daniel Gregory Brennan

• Topic: Clinical revenue guidance revision and reimbursement timeline
• Key points:
  • Clinical revenue guide narrowed from $3M–$10M to $3M–$6M, due to fewer months before reimbursement now visible (August).
  • Previously modeled reimbursement for 1 indication in late Q3 and 1 in Q4; now expects both cancer types in Q4.
  • 3 "shots on goal" (IO submission, TRACERx lung data, existing engagement) to get 2 indications by year-end.
• Mgmt stance: Neutral – confident in evidence meeting Palmetto bar, but exact timeline remains uncertain.

Q2 — Vidyun Bais

• Topic: Biopharma revenue reduction and MRD growth drivers
• Key points:
  • $10M guide cut (from $62M–$64M to $52M–$58M) attributed to translational project delays, not cancellations; revenues expected to convert in 2–4 quarters.
  • Moderna personalized cancer vaccine deal is "on pace"; revenue decline expected as melanoma trial enrollment slowed.
  • MRD product (NeXT Personal) seeing 300%–400% growth; no MRD projects slipping; 2 new customers >$5M each.
• Mgmt stance: Neutral – cautious on biopharma translational softness; bullish on MRD performance and retention.

Q3 — Thomas Flaten

• Topic: Operational scaling, physician testing cadence, and Tempus sales model
• Key points:
  • Turnaround times have "fallen dramatically" after 18 months of R&D scaling; now comparable to other vendors.
  • Recurrence monitoring cadence lower than therapy monitoring; IO therapy monitoring sees highest frequency – still early to quantify.
  • Tempus handles majority of physician logistics via EMR integration; Personalis reps focus on KOLs and non-Tempus accounts.
• Mgmt stance: Bullish – execution solid, retention and growth driven by operational reliability.

Q4 — Yih-Ming Tu

• Topic: Biopharma policy headwinds, competitive differentiation vs. Saga, margin vs. growth balance
• Key points:
  • Biopharma guide cut to $52M–$58M due to translational project delays; MRD funnel growing with 2 $5M customers on track.
  • Saga received breast cancer reimbursement; Personalis sees this as validation, with own breast/lung/IO submissions and planned neoadjuvant breast submission.
  • Tempus arrangement provides sales/marketing leverage without heavy upfront investment; 30%–40% growth target, currently 50%+ sequential growth.
• Mgmt stance: Bullish – differentiated by whole-genome 1,800-variant approach and prospective trials (Be Stronger, PREDICT); focused on high-volume run rate before reimbursement.

Q5 — Subhalaxmi T. Nambi

• Topic: ASCO data impact, pricing expectations, and physician interest amid reimbursement delay
• Key points:
  • ASCO introduced first neoadjuvant breast cancer data (PREDICT, SCANDARE): test highly predictive of relapse independent of pCR, setting up future MolDx submission.
  • No pricing discussions until coverage obtained; models assume current reimbursement rates (~similar to 16-variant exome test) as floor.
  • No erosion in physician interest; still have wait list; 600+ physicians ordering, expanding deeper into accounts.
• Mgmt stance: Bullish – ultrasensitive range driving retention; pricing upside possible given higher resource cost of whole-genome approach.

Q&A Batch (6-8 of 8)

Q6 — Michael Stephen Matson

• Topic: Tempus arrangement and reimbursement ramp for lung/breast cancer
• Key points:
  • Most samples (from PSNL and Tempus) fall within lung, breast, immunotherapy monitoring, and increasingly CRC; not "all over the map".
  • If lung or breast cancer coverage is obtained first, there is opportunity to "preferentially focus" on physicians treating those types, but cannot tell physicians to send only those patients.
  • For CRC reimbursement: Victory data is "phenomenal" but preliminary; it is a prospective study (not retrospective). Investigator has not yet decided when to publish; submission timing is TBD.
• Mgmt stance: Neutral — mgmt acknowledges limited control to fully steer physician behavior, and CRC reimbursement timeline remains uncertain.

Q7 — Swayampakula Ramakanth

• Topic: Pharma test & services revenue slowdown and full-year outlook
• Key points:
  • MRD side inside biopharma customers is on track: 300%–400% annual growth, couple of new customers generating north of $5 million.
  • Translational research phase (tumor profiling for biomarker discovery) experienced slowness, driven by drug development process questions, drug pricing, tariffs, and layoffs in some companies.
  • Full-year guidance for translational product: expected to be "flattish to a little bit of growth" year-over-year; not in a tailspin, but earlier pipeline expectations were higher.
  • MRD explosive growth remains on track; translational slowdown deepened as Q2 progressed, prompting prudent guidance adjustment.
• Mgmt stance: Cautious on translational segment (temporary slowdown due to macro factors), bullish on MRD (on plan, strong growth).

Q8 — Aaron L. Tachibana

• Topic: Mechanics of Medicare coverage decision and revenue guidance
• Key points:
  • Key fact: favorable coverage decision from Medicare is the primary goal.
  • Assuming favorable coverage for 2 cancer types, guidance is $3 million to $6 million.
  • Variability in range depends on timing, number of samples, and price.
• Mgmt stance: Neutral — focus on achieving favorable Medicare decision; revenue range reflects inherent uncertainty.